Abdul Mannan Inside the Diagnostic Maze of Atypical CML
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
”It’s rare. It’s aggressive. It mimics other blood cancers.
No Philadelphia chromosome. No targeted therapy. Just tough decisions.
Diagnosis needs sharp eyes. Dysplastic cells. High white counts. Molecular clues.
SETBP1 and ASXL1 mutations tell the story.
CSF3R points elsewhere.
Median survival? 14-30 months without transplant.
But here’s hope: Early recognition matters. Molecular testing guides us. Transplant can cure selected patients.
Every rare diagnosis teaches us something profound about blood biology.
As haematologists, we don’t just treat diseases. We solve puzzles that save lives.
What rare condition taught you the most?”
Keep up with Hemostasis Today.
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC